{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,5,31]],"date-time":"2024-05-31T04:28:53Z","timestamp":1717129733580},"reference-count":15,"publisher":"American Society of Hematology","issue":"3","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2007,2,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>We have reported that anti-idiotype antibody response and Fc\u03b3RIIIa 158 valine\/valine (V\/V) genotype both correlate with better outcome in a group of 136 follicular lymphoma patients receiving idiotype vaccination after induction chemotherapy. Here, we examined whether this correlation is related in any way to the chemotherapy response. In patients with complete response (CR), the 5-year progression-free survival (PFS) was 69% for patients with antibody response and\/or V\/V genotype, while the PFS was only 40% for patients with neither; the median time to progression (TTP) was 10.47 versus 3.46 years (P = .012). In patients with partial response (PR), the 5-year PFS was 57% for patients with antibody response and\/or V\/V genotype, and 17% for patients with neither; the median TTP was not reached versus 1.31 years (P = .001). This study further confirms the strong association of clinical outcome with antibody response and with the functionally more active form of the Fc receptor in patients receiving idiotype vaccination regardless of their response to induction chemotherapy.<\/jats:p>","DOI":"10.1182\/blood-2006-03-013136","type":"journal-article","created":{"date-parts":[[2006,10,11]],"date-time":"2006-10-11T02:56:53Z","timestamp":1160535413000},"page":"951-953","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":26,"title":["Humoral immune response and immunoglobulin G Fc receptor genotype are associated with better clinical outcome following idiotype vaccination in follicular lymphoma patients regardless of their response to induction chemotherapy"],"prefix":"10.1182","volume":"109","author":[{"given":"Wen-Kai","family":"Weng","sequence":"first","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Debra","family":"Czerwinski","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ronald","family":"Levy","sequence":"additional","affiliation":[{"name":"Division of Medical Oncology, Department of Internal Medicine, Stanford University School of Medicine, Stanford, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","published-online":{"date-parts":[[2006,10,10]]},"reference":[{"key":"2019111713445011400_B1","doi-asserted-by":"crossref","unstructured":"Kwak LW, Campbell MJ, Czerwinski DK, Hart S, Miller RA, Levy R. Induction of immune responses in patients with B-cell lymphoma against the surface-immunoglobulin idiotype expressed by their tumors. N Engl J Med1992; 327:1209\u20131215.","DOI":"10.1056\/NEJM199210223271705"},{"key":"2019111713445011400_B2","unstructured":"Ruffini PA, Neelapu SS, Kwak LW, Biragyn A. Idiotype vaccination for B-cell malignancies as a model for therapeutic cancer vaccines. Haematologica2002; 87:989\u20131001."},{"key":"2019111713445011400_B3","doi-asserted-by":"crossref","unstructured":"Osterroth F, Garbe A, Fisch P, Veelken H. Stimulation of cytotoxic T cells against idiotype immunoglobulin of malignant lymphoma with protein-pulsed or idiotype-transduced dendritic cells. Blood2000; 95:1342\u20131349.","DOI":"10.1182\/blood.V95.4.1342.004k19_1342_1349"},{"key":"2019111713445011400_B4","doi-asserted-by":"crossref","unstructured":"McCarthy H, Ottensmeier CH, Hamblin TJ, Stevenson FK. Anti-idiotype vaccines. Brit J Haematol2003; 123:770\u2013781.","DOI":"10.1046\/j.1365-2141.2003.04698.x"},{"key":"2019111713445011400_B5","doi-asserted-by":"crossref","unstructured":"Hsu FJ, Caspar CB, Czerwinski D, et al. Tumor-specific idiotype vaccines in the treatment of patients with B-cell lymphoma: long-term results of a clinical trial. Blood1997; 89:3129\u20133135.","DOI":"10.1182\/blood.V89.9.3129"},{"key":"2019111713445011400_B6","doi-asserted-by":"crossref","unstructured":"Bendandi M, Gocke CD, Kobrin CB, et al. Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma. Nat Med1999; 5:1171\u20131177.","DOI":"10.1038\/13928"},{"key":"2019111713445011400_B7","doi-asserted-by":"crossref","unstructured":"Weng W-K, Czerwinski D, Timmerman J, Hsu FJ, Levy R. Clinical outcome of lymphoma patients after idiotype vaccination is correlated with humoral immune response and immunoglobulin G Fc receptor genotype. J Clin Oncol2004; 22:4717\u20134724.","DOI":"10.1200\/JCO.2004.06.003"},{"key":"2019111713445011400_B8","doi-asserted-by":"crossref","unstructured":"Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphoma. J Clin Oncol1999; 17:1244\u20131253.","DOI":"10.1200\/JCO.1999.17.4.1244"},{"key":"2019111713445011400_B9","doi-asserted-by":"crossref","unstructured":"Solal-Celigny P, Roy P, Colombat P, et al. Follicular lymphoma international prognostic index. Blood2004; 104:1258\u20131265.","DOI":"10.1182\/blood-2003-12-4434"},{"key":"2019111713445011400_B10","doi-asserted-by":"crossref","unstructured":"Timmerman JM, Czerwinski DK, Davis TA, et al. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood2002; 99:1517\u20131526.","DOI":"10.1182\/blood.V99.5.1517"},{"key":"2019111713445011400_B11","doi-asserted-by":"crossref","unstructured":"Hsu FJ, Benike C, Fagnoni F, et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nat Med1996; 2:52\u201358.","DOI":"10.1038\/nm0196-52"},{"key":"2019111713445011400_B12","doi-asserted-by":"crossref","unstructured":"Kopreski MS, Benko FA, Kwee C, et al. Detection of mutant K-ras DNA in plasma or serum of patients with colorectal cancer. Br J Cancer1997; 76:1293\u20131299.","DOI":"10.1038\/bjc.1997.551"},{"key":"2019111713445011400_B13","doi-asserted-by":"crossref","unstructured":"Wijermans PW, Gerrits WB, Haak HL. Severe immunodeficiency in patients treated with fludarabine monophosphate. Eur J Haematol1993; 50:292\u2013296.","DOI":"10.1111\/j.1600-0609.1993.tb00165.x"},{"key":"2019111713445011400_B14","doi-asserted-by":"crossref","unstructured":"Kwak LW. Tumor vaccination strategies combined with autologous peripheral stem cell transplantation. Ann Oncol1998; 9:suppl 1, S41\u2013S46.","DOI":"10.1093\/annonc\/9.suppl_1.S41"},{"key":"2019111713445011400_B15","doi-asserted-by":"crossref","unstructured":"Hurvitz SA and Timmerman JM. Recombinant, tumor-derived idiotype vaccination for indolent B cell non-Hodgkin's lymphoma: a focus on FavId. Expert Opin Biol Ther2005; 5:841\u2013852.","DOI":"10.1517\/14712598.5.6.841"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/109\/3\/951\/1287783\/zh800307000951.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/109\/3\/951\/1287783\/zh800307000951.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,17]],"date-time":"2019-11-17T18:45:02Z","timestamp":1574016302000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/109\/3\/951\/23889\/Humoral-immune-response-and-immunoglobulin-G-Fc"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,10,10]]},"references-count":15,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2006,10,10]]},"published-print":{"date-parts":[[2007,2,1]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2006-03-013136","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,10,10]]}}}